FDA approves first treatment for Menkes disease in children

The U.S. Food and Drug Administration has approved the Zycubo (copper histidinate) injection as the first treatment for ...
Medscape

Fremanezumab for Pediatric Migraine Prevention: Phase 3 SPACE Trial Results

Results of the SPACE trial demonstrating the safety and efficacy of subcutaneous fremanezumab for the prevention of pediatric ...
Monthly Prescribing Reference

FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab

The product is administered over a period of 3 to 5 minutes into the subcutaneous tissue of the abdomen or thigh by a health care provider. Opdivo Qvantig combines nivolumab, a programmed death ...
WebMD

Subcutaneous Injections

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...
Seeking Alpha

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...
Neurology Advisor

First Treatment for Menkes Disease: FDA Approves Copper Histidinate

The Food and Drug Administration (FDA) has approved Zycubo® (copper histidinate) for the treatment of Menkes disease in pediatric patients.
Nasdaq

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...